Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

XALKORI 20 MG GRANULADO EN CAPSULAS PARA ABRIR - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/XALKORI 20 MG GRANULADO EN CAPSULAS PARA ABRIR

Approved

STANDARD

XALKORI 20 MG GRANULADO EN CAPSULAS PARA ABRIR

Pfizer Europe Ma Eeig🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Sep 20, 2024
Approval ID: 1785126393c2ab2a
Company: Pfizer Europe Ma Eeig
Type: Standard

Approval Details

Approval Id: 1785126393c2ab2a
Drug Cima Aemps Name: XALKORI 20 MG GRANULADO EN CAPSULAS PARA ABRIR
Register Number: 112793005
Holder Company Name: Pfizer Europe Ma Eeig
Marketing Company Name: Pfizer S.L.
Holder Company Detail Path: /organization/pfizer-europe-ma-eeig
Authorization Date: 2024-09-20
Dosage Form: GRANULADO EN CAPSULAS PARA ABRIR
Dose: 20 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Pfizer Europe Ma Eeig
Company Detail Path: /organization/pfizer-europe-ma-eeig

Company Information

Pharmaceutical Company Name: Pfizer Europe MA EEIG
Country Name: United Kingdom

Active Ingredients

CRIZOTINIB

20 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Sep 20, 2024

Approval ID

1785126393c2ab2a

Type

Standard

Back to CIMA-AEMPS Approvals